Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13 EUR | +8.33% | -.--% | -.--% |
30/04 | Bayer: strategic collaboration with Evotec | CF |
30/04 | Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies | MT |
Sales 2024 * | 881M 940M 78.46B | Sales 2025 * | 1.05B 1.12B 93.88B | Capitalization | 1.73B 1.84B 154B |
---|---|---|---|---|---|
Net income 2024 * | 10M 10.67M 891M | Net income 2025 * | 73M 77.9M 6.5B | EV / Sales 2024 * | 1.78 x |
Net cash position 2024 * | 161M 172M 14.34B | Net cash position 2025 * | 166M 178M 14.82B | EV / Sales 2025 * | 1.48 x |
P/E ratio 2024 * |
71.2
x | P/E ratio 2025 * |
17.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec
1 day | +8.33% |
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07/23/07 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19/19/19 |
Chairman | 63 | 17/14/17 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- EVT Stock
- EVT Stock